The role of the prostaglandin EP 4 receptor in the regulation of human outflow facility

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 6, 2011, Pages 3506-3513

  Millard, Lindsay H ^a   Woodward, David F ^b   Daniel Stamer, W ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b ALLERGAN INC   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 7 DITHIA PROSTAGLANDIN E1; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; BETA ARRESTIN; CYCLIC AMP; GW 627368; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG; 3,7 DITHIA(11 ALPHA,13E,15S) 11,15 DIHYDROXY 9 OXOPROST 13 EN 1 OIC ACID; 3,7-DITHIA(11 ALPHA,13E,15S)-11,15-DIHYDROXY-9-OXOPROST-13-EN-1-OIC ACID; DRUG DERIVATIVE; ISOINDOLE DERIVATIVE; N (2 (4 (4,9 DIETHOXY 1 OXO 1,3 DIHYDRO 2H BENZO(F)ISOINDOL 2 YL)PHENYL)ACETYL)BENZENE SULPHONAMIDE; N-(2-(4-(4,9-DIETHOXY-1-OXO-1,3-DIHYDRO-2H-BENZO(F)ISOINDOL-2-YL)PHENYL)ACETYL)BENZENE SULPHONAMIDE; PROSTAGLANDIN E1; RETINA S ANTIGEN; SULFONAMIDE;

AQUEOUS HUMOR OUTFLOW; ARTICLE; BIOTINYLATION; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; LASER MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHLEMM CANAL; TRABECULAR MESHWORK; WESTERN BLOTTING; AQUEOUS HUMOR; CELL CULTURE; CORNEA; DONOR; DOSE RESPONSE; DRUG EFFECT; FLUORESCENCE MICROSCOPY; INTRAOCULAR PRESSURE; METABOLISM; PHYSIOLOGY; SCLERA; SECRETION;

ALPROSTADIL; AQUEOUS HUMOR; ARRESTINS; BLOTTING, WESTERN; CELLS, CULTURED; CORNEA; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTRAOCULAR PRESSURE; ISOINDOLES; MICROSCOPY, FLUORESCENCE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; SCLERA; SULFONAMIDES; TISSUE DONORS; TRABECULAR MESHWORK;

EID: 80051765713     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6510     Document Type: Article

References (30)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80(5):389-393.
2. Niesel P, Flammer J. Correlations between intraocular pressure, visual field and visual acuity, based on 11 years of observations of treated chronic glaucomas. Int Ophthalmol. 1980;3(1):31-35.
3. Gabelt BT, Kaufman PL. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989;49(3): 389-402.
4. Lindsey JD, Kashiwagi K, Boyle D, Kashiwagi F, Firestein GS, Weinreb RN. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res. 1996;15(8):869-875.
5. Bahler CK, Howell KG, Hann CR, Fautsch MP, Johnson DH. Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am J Ophthalmol. 2008;145(1): 114-119.
6. Bhattacherjee P, Williams BS, Paterson CA. Responses of intraocular pressure and the pupil of feline eyes to prostaglandin EP1 and FP receptor agonists. Invest Ophthalmol Vis Sci. 1999;40(12): 3047-3053.
7. Dijkstra BG, Schneemann A, Hoyng PF. Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999;40(11):2622-2626.
8. Prasanna G, Fortner J, Xiang C, et al. Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models. Exp Eye Res. 2009;89(5):608-617.
9. Woodward DF, Nilsson SF, Toris CB, Kharlamb AB, Nieves AL, Krauss AH. Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow. Invest Ophthalmol Vis Sci. 2009;50(7):3320-3328.
10. Waterbury LD, Eglen RM, Faurot GF, Cooper GF. EP3, but not EP2, FP, or TP prostanoid-receptor stimulation may reduce intraocular pressure. Invest Ophthalmol Vis Sci. 1990;31(12):2560-2567.
11. Crawford K, Kaufman PL, Gabelt BT. Effects of topical PGF2 alpha on aqueous humor dynamics in cynomolgus monkeys. Curr Eye Res. 1987;6(8):1035-1044.
12. Griffin BW, Klimko P, Crider JY, Sharif NA. AL-8810: a novel prostaglandin F2 alpha analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor. J Pharmacol Exp Ther. 1999;290(3):1278-1284.
13. Toris CB, Zhan GL, Zhao J, Camras CB, Yablonski ME. Potential mechanism for the additivity of pilocarpine and latanoprost. Am J Ophthalmol. 2001;131(6):722-728.
14. Woodward DF, Krauss AH, Nilsson SF. Bimatoprost effects on aqueous humor dynamics in monkeys. J Ophthalmol. 2010;2010: 926192.
15. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111(10):1351-1358.
16. Stamer WD, Seftor RE, Williams SK, Samaha HA, Snyder RW. Isolation and culture of human trabecular meshwork cells by extracellular matrix digestion. Curr Eye Res. 1995;14(7):611-617.
17. Stamer WD, Roberts BC, Howell DN, Epstein DL. Isolation, culture, and characterization of endothelial cells from Schlemm's canal. Invest Ophthalmol Vis Sci. 1998;39(10):1804-1812.
18. Fujino H, West KA, Regan JW. Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J Biol Chem. 2002;25 277(4):2614-2619.
19. Stamer WD, Huang Y, Seftor RE, Svensson SS, Snyder RW, Regan JW. Cultured human trabecular meshwork cells express functional alpha 2A adrenergic receptors. Invest Ophthalmol Vis Sci. 1998; 37(12):2426-2433.
20. Stamer WD, Read AT, Sumida GM, Ethier CR. Sphingosine-1-phosphate effects on the inner wall of Schlemm's canal and outflow facility in perfused human eyes. Exp Eye Res. 2009;89(6):980-988.
21. Ethier CR, Ajersch P, Pirog R. An improved ocular perfusion system. Curr Eye Res. 1993;12(8):765-770.
22. Schlotzer-Schrehardt U, Zenkel M, Nusing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci. 2002;43(5):1475-1487.
23. Bhattacharya M, Peri K, Ribeiro-da-Silva A, et al. Localization of functional prostaglandin E2 receptors EP3 and EP4 in the nuclear envelope. J Biol Chem. 1999;274(22):15719-15724.
24. Mukhopadhyay P, Geoghegan TE, Patil RV, Bhattacherjee P, Paterson CA. Detection of EP2, EP4, and FP receptors in human ciliary epithelial and ciliary muscle cells. Biochem Pharmacol. 1997; 53(9):1249-1255.
25. Crider JY, Sharif NA. Functional pharmacological evidence for EP2 and EP4 prostanoid receptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells. J Ocul Pharmacol Ther. 2001;17(1):35-46.
26. Stamer WD, Piwnica D, Jolas T, et al. Cellular basis for bimatoprost effects on human conventional outflow. Invest Ophthalmol Vis Sci. 2010;51(10);5176-5181.
27. Fujino H, Salvi S, Regan JW. Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. Mol Pharmacol. 2005;68(1):251-259.
28. Woodward DF, Pepperl DJ, Burkey TH, et al. 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid (AH6809), a human EP2 receptor antagonist. Biochem Pharmacol. 1995;50:1731-1732.
29. Lydford SJ, McKechnie KC, Leff P. Interaction of BW A868C, a prostanoid DP-receptor antagonist, with two receptor subtypes in the rabbit isolated saphenous vein. Prostaglandins. 1996;52(2): 125-139.
30. Hoyng PF, de Jong N. Iloprost, a stable prostacyclin analog, reduces intraocular pressure. Invest Ophthalmol Vis Sci. 1987;3: 470-476.